Health Executives Partner to Create Pioneering Women’s Health AI Initiative
The women’s health industry is entering a transformative new era with the launch of the Women’s Health AI Consortium, a groundbreaking initiative created to establish the first clinically rigorous and transparent standards for artificial intelligence in women’s healthcare. The consortium brings together leaders from across the health technology ecosystem, including Willow, Ema EQ, Clue, Oura, Carrot Fertility, and other prominent innovators, all united by a shared mission: ensuring that AI solutions designed for women are safe, ethical, evidence-based, and inclusive.
Announced in San Francisco, the formation of the consortium marks a significant milestone for the rapidly expanding field of women’s health technology, commonly referred to as femtech. The initiative was co-founded by Willow Innovations, Inc., widely recognized for revolutionizing the breast-pumping experience for mothers through wearable technology, and Ema EQ, a company focused on developing artificial intelligence solutions specifically tailored to women’s health needs.
The Women’s Health AI Consortium is the first industry-wide body dedicated exclusively to creating common benchmarks, ethical frameworks, and evaluation standards for artificial intelligence applications in women’s health. Its formation comes at a critical moment as AI technologies are increasingly integrated into healthcare products, diagnostics, wellness platforms, fertility services, maternal care tools, and mental health support systems.
For decades, women’s health has remained underrepresented in clinical research, healthcare innovation, and technology investment. Many medical studies historically relied on male-centric datasets, leaving significant gaps in understanding how diseases, treatments, and healthcare experiences uniquely affect women. As artificial intelligence systems become more influential in healthcare decision-making, experts warn that these historical gaps risk being amplified if AI tools are built using incomplete or biased data.
The consortium aims to address these concerns before flawed systems become deeply embedded in healthcare infrastructure. By creating industry-wide standards and accountability measures, the organization seeks to ensure that women are not left behind in the AI revolution.
Sarah O’Leary, CEO of Willow, emphasized the urgency of establishing oversight and accountability in the growing women’s health AI market. According to O’Leary, artificial intelligence is advancing faster than regulatory and ethical standards can currently keep pace, making collaborative governance essential.
She explained that the consortium is intended to provide the industry with a clear and unified framework grounded in clinical evidence, real-world experiences, and measurable accountability. Rather than allowing companies to independently define safety and effectiveness standards, the initiative aims to create shared expectations that place women’s needs and wellbeing at the center of AI development.
The consortium’s leadership believes that women deserve healthcare technologies built specifically with their biological, emotional, and social realities in mind. They argue that too many digital health tools have historically overlooked the complexity of women’s health experiences or failed to incorporate sufficient diversity in their training data and evaluation methods.
Amanda Ducach, CEO of Ema EQ, said the company has seen firsthand how AI can positively impact women’s health outcomes when developed responsibly. However, she stressed that without strong safeguards, oversight, and clinical rigor, AI systems also carry significant risks, including bias, misinformation, and inaccurate recommendations.
Ducach noted that the consortium was created because the stakes are too high to leave ethical standards to chance. She emphasized that women deserve AI systems that are clinically safe, culturally aware, transparent about their limitations, and intentionally designed in partnership with women rather than simply marketed to them.
To guide its mission, the Women’s Health AI Consortium has established a governance framework built around six major commitments designed to shape the future of responsible AI development in women’s healthcare.
The first commitment focuses on ethical and safety standards. Consortium members aim to ensure that AI tools undergo robust testing, maintain clinical integrity, and prioritize patient safety throughout development and deployment.
The second pillar centers on bias reduction and cultural integrity. Recognizing that many AI systems reflect biases present in historical datasets, the consortium plans to encourage the use of more diverse, representative, and inclusive data sources to better serve women from different backgrounds, cultures, and health experiences.
The third area addresses emotional and clinical quality at scale. Women’s health often involves deeply personal experiences, including fertility, pregnancy, menopause, reproductive health, and mental wellbeing. Consortium leaders believe AI systems must demonstrate not only technical accuracy but also empathy, emotional sensitivity, and contextual understanding.
Another core principle is contextual and longitudinal intelligence. Rather than treating health concerns as isolated incidents, consortium members advocate for AI systems that understand long-term health patterns and the evolving nature of women’s healthcare journeys across different life stages.
The organization also plans to support mentorship and education for ethical AI builders. By encouraging collaboration between clinicians, engineers, researchers, ethicists, and entrepreneurs, the consortium hopes to cultivate a new generation of healthcare innovators committed to responsible technology development.
Finally, the consortium prioritizes transparent oversight and continuous improvement. Member organizations are expected to remain open about how their AI systems are trained, validated, and monitored. The consortium intends to promote ongoing evaluation and accountability rather than one-time certification processes.
Industry experts believe the initiative could play a major role in shaping public trust in women’s health AI technologies. As consumers increasingly rely on digital health platforms for information and care guidance, transparency and reliability are becoming critical competitive advantages for healthcare companies.
The consortium’s founders also emphasize that the initiative is not intended to limit innovation. Instead, they view the standards as a way to strengthen the overall ecosystem by creating clearer expectations for quality, safety, and trustworthiness. Organizations developing AI solutions for women’s health may benefit from having standardized reference points for product design, validation, procurement, and regulatory discussions.
In addition to benefiting companies, the initiative is expected to empower women by giving them greater confidence in the tools they use. By establishing clearer standards, the consortium hopes women will be better informed about how AI systems work, what data they rely on, and where their limitations exist.
The Women’s Health AI Consortium is governed by a multidisciplinary board composed of leaders from healthcare, technology, ethics, science, and law. The board includes Sarah O’Leary of Willow; Amanda Ducach and Morgan Rose from Ema EQ; Audrey Tsang, former CEO and board member at Clue; Tanvi Jayaraman, Clinical Lead at Oura; and Asima Ahmad, Chief Medical Officer at Carrot Fertility.
The group also includes Ethan Cowan, who holds a PhD in the history and philosophy of science and technology, reflecting the consortium’s broader commitment to ethical reflection and interdisciplinary collaboration. Jennifer Yoo, a partner at Latham & Watkins, serves as a board observer, bringing legal and regulatory insight to the initiative.
The launch of the consortium reflects a broader trend in healthcare as industry leaders increasingly recognize the need for ethical governance around artificial intelligence. While AI has the potential to improve diagnostics, personalize treatment plans, increase healthcare access, and reduce administrative burdens, concerns about bias, misinformation, privacy, and unequal outcomes continue to grow.
Women’s health presents particularly unique challenges because many conditions affecting women remain underdiagnosed, misunderstood, or insufficiently studied. AI systems trained on incomplete data could unintentionally reinforce those disparities unless developers actively address them.
Consortium members believe that future AI systems should meet rigorous accuracy standards, contribute to closing longstanding knowledge gaps in women’s health, and remain transparent about their data sources and methodologies. They also argue that AI companies should communicate honestly about what their tools can and cannot do, ensuring that users understand both the strengths and limitations of AI-generated insights.
Ultimately, the Women’s Health AI Consortium aims to redefine what trustworthy AI looks like in women’s healthcare. By promoting collaboration, accountability, transparency, and evidence-based innovation, the initiative seeks to help the healthcare industry finally deliver the level of attention, safety, and clinical rigor that women have long deserved.
As AI continues to reshape the future of healthcare, the consortium’s leaders hope their efforts will set a new global standard for responsible innovation—one where women’s experiences are no longer treated as an afterthought, but as a central priority in the design and evaluation of emerging healthcare technologies.
About The Women’s Health AI Consortium
The Women’s Health AI Consortium aims to close the gap between the pace of AI development and the standards that guide it. Today, models are trained on data that under-represent women and without clinical review. The Consortium, established by clinicians, technologists, ethicists, and regulators, is developing the first shared benchmarks and governance framework for AI that serves women’s health.
